<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290237</url>
  </required_header>
  <id_info>
    <org_study_id>10-11-0561</org_study_id>
    <nct_id>NCT01290237</nct_id>
  </id_info>
  <brief_title>Use of a Loading Dose of Vancomycin in Pediatric Dosing</brief_title>
  <official_title>The Use of a Loading Dose of Intravenous Vancomycin Will Achieve Therapeutic Concentration Earlier Than Conventional Pediatric Dosing: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is an antibiotic administered to children or adults for many types of infections.
      While it has been used to treat infections of children for more than 50 years we are still
      not completely certain about the best dose to use when starting treatment with this
      medication.

      This study is intended to evaluate whether giving a new higher dose of vancomycin for the
      first dose will help us get to the desired amount in the body more quickly then the usual
      first dose. Half of the patients would get the new higher dose and the other half of patients
      will get the typical first dose. Only the first dose is changed and all doses that follow are
      the same in both groups and are doses typically used for children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Setting and Patients We conducted a double-blind randomized controlled trial of children aged
      2 to 18 years hospitalized at Boston Children's Hospital between February 1, 2011, and
      January 15, 2012, who required antimicrobial therapy with vancomycin (Hospira, Inc., Lake
      Forest, IL, lot #896188EO-4) for a suspected or documented infection. We excluded patients
      with a body weight above 67 kg (to limit the maximum loading dose to 2 g), preexisting severe
      renal dysfunction, defined as creatinine clearance &lt;50 mL/min/1.73m2 using the original
      Schwartz equation,7 known hearing impairment, intravenous vancomycin treatment in the prior 7
      days or undergoing a procedure with anticipated moderate to severe blood loss (eg, cardiac
      surgery or extensive orthopedic procedure).

      For all participants enrolled in the study, relevant baseline demographic, medical history
      and safety data were recorded. Medical history data included primary and secondary diagnoses;
      other comorbidities such as obesity or cystic fibrosis; and presence of systemic inflammatory
      response syndrome, defined as 2 or more of the following: temperature &gt;38.5°C or &lt;36°C; mean
      heart rate &gt;2 standard deviations above normal for age; mean respiratory rate &gt;2 standard
      deviations above normal for age; or high or low white blood cell count for age.

      Randomization and Concealment Participants were randomized in blocks of 2 and 4 to receive
      either a loading dose of 30 mg/kg of vancomycin as a single intravenous infusion over 2 hours
      (intervention group) or an initial vancomycin dose of 20 mg/kg intravenously over 2 hours
      (comparison group). The initial dose was administered over 2 hours in both groups to preserve
      allocation concealment. All patients subsequently received a 20 mg/kg dose every 8 hours as
      was the standard of care in our hospital for treatment of severe infections at the time of
      the study. Subsequent doses were administered over 1 hour, unless the patient developed red
      man syndrome (as identified by the clinical team), in which case the infusion time was
      increased to 2 hours. The investigators, family and primary care teams were blinded to group
      assignment, and the first dose of vancomycin for all participants was prepared so that the
      solution volumes were identical. The computer-generated randomization was concealed in a
      locked binder until the intervention was assigned.

      Vancomycin Concentration Sampling and Analysis Trough serum vancomycin concentrations were
      obtained within 60 minutes before the second (8-hour) and third (16-hour) vancomycin doses.
      In order to increase the likelihood of having a cloud of sparse data for population
      pharmacokinetic analysis, 1 or 2 additional serum vancomycin samples were obtained from each
      participant within the first 32 hours of therapy at a time coinciding with blood collection
      for clinical care. These samples were obtained only from participants with an indwelling
      catheter whose family provided written consent for additional sampling.

      Vancomycin concentrations were measured using a fluorescence polarization immunoassay (Roche
      Diagnostics, Indianapolis, IN) on the Roche Integra 800 instrument. The assay had a limit of
      quantitation of 0.74 mg/L and an interassay coefficient of variability of &lt;3%.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI leaving institution, slow enrollment
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Participants With Vancomycin Trough Between 15 and 20</measure>
    <time_frame>8 hours after the first dose of vancomycin</time_frame>
    <description>proportion of participants whose vancomycin trough was between 15 and 20 mcg/mL, 8 hours after the first vancomycin dose, in loading dose group as compared to control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC/MIC for Vancomycin in the Study Population</measure>
    <time_frame>within 48 hours after receiving the first dose of vancomycin</time_frame>
    <description>AUC/MIC using hypothetical MIC = 1 mg/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin hydrocloride</intervention_name>
    <description>see description of study arms</description>
    <arm_group_label>Vancomycin loading dose</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving care at Children's Hospital Boston

          -  Prescribed intravenous vancomycin by their physician

        Exclusion Criteria:

          -  Weight above 67 kg

          -  Pre-existing renal dysfunction (creatinine clearance &lt; 50 ml/min/1.73m2)

          -  Known hearing impairment

          -  Recent intravenous vancomycin treatment (within 7 days)

          -  Undergoing procedure with anticipated moderate-severe blood loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia A Demirjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434. Review. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887.</citation>
    <PMID>19106348</PMID>
  </reference>
  <reference>
    <citation>Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009 May;28(5):398-402. doi: 10.1097/INF.0b013e3181906e40.</citation>
    <PMID>19295465</PMID>
  </reference>
  <reference>
    <citation>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4. Erratum in: Clin Infect Dis. 2011 Aug 1;53(3):319.</citation>
    <PMID>21208910</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <results_first_submitted>April 15, 2017</results_first_submitted>
  <results_first_submitted_qc>February 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2018</results_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Alicia Demirjian</investigator_full_name>
    <investigator_title>Clinical Fellow, Pediatric Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>vancomycin</keyword>
  <keyword>loading dose</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pediatric</keyword>
  <keyword>Methicillin-Resistant Staphylococcus aureus (MRSA)</keyword>
  <keyword>Serious infection with Gram positive bacteria</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vancomycin Loading Dose</title>
          <description>Intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Intravenous vancomycin 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vancomycin Loading Dose</title>
          <description>Intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Intravenous vancomycin 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.63" spread="4.4"/>
                    <measurement group_id="B2" value="8.76" spread="4.04"/>
                    <measurement group_id="B3" value="8.70" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants With Vancomycin Trough Between 15 and 20</title>
        <description>proportion of participants whose vancomycin trough was between 15 and 20 mcg/mL, 8 hours after the first vancomycin dose, in loading dose group as compared to control group</description>
        <time_frame>8 hours after the first dose of vancomycin</time_frame>
        <population>Loading dose - trough at 8 hours was not collected for 11 participants: vancomycin was discontinued prior to second dose (7), participant changed their mind (1), other reason (3) Among participants allocated to conventional treatment, trough at 8 hours was not collected for 2: vancomycin discontinued prior to second dose (1), changed mind (1)</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin Loading Dose</title>
            <description>Intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Intravenous vancomycin 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Vancomycin Trough Between 15 and 20</title>
          <description>proportion of participants whose vancomycin trough was between 15 and 20 mcg/mL, 8 hours after the first vancomycin dose, in loading dose group as compared to control group</description>
          <population>Loading dose - trough at 8 hours was not collected for 11 participants: vancomycin was discontinued prior to second dose (7), participant changed their mind (1), other reason (3) Among participants allocated to conventional treatment, trough at 8 hours was not collected for 2: vancomycin discontinued prior to second dose (1), changed mind (1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC/MIC for Vancomycin in the Study Population</title>
        <description>AUC/MIC using hypothetical MIC = 1 mg/L</description>
        <time_frame>within 48 hours after receiving the first dose of vancomycin</time_frame>
        <population>Number of measurements reflects the number of blood samples available for testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Loading Dose</title>
            <description>As above</description>
          </group>
          <group group_id="O2">
            <title>Conventional Dose</title>
            <description>as above</description>
          </group>
        </group_list>
        <measure>
          <title>AUC/MIC for Vancomycin in the Study Population</title>
          <description>AUC/MIC using hypothetical MIC = 1 mg/L</description>
          <population>Number of measurements reflects the number of blood samples available for testing.</population>
          <units>AUC/MIC ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.5" spread="195.5"/>
                    <measurement group_id="O2" value="434.0" spread="153.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vancomycin Loading Dose</title>
          <description>Intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Intravenous vancomycin 20 mg/kg/dose every 8 hours
intravenous vancomycin hydrochloride: see description of study arms</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <description>One patient with cystic fibrosis developed acute kidney injury 7 days after administration of a conventional dose while receiving concomitant nephrotoxic medications; renal function recovered when these medications and vancomycin were discontinued.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Escalation of care within 7 days</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Doubling of baseline creatinine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>trial underpowered to detect an increase of ≥40% in concentrations (small sample size)
more cases excluded in the high-dose group than in reference group (possible analysis bias)
increase in red man syndrome in the high-dose group</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alicia Demirjian</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <email>alicia.demirjian@post.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

